Imaging In Evaluation Of Patients With Cushing Syndrome

10%-20%的皮质醇增多症患者（库欣？S综合征）具有促肾上腺皮质激素（ACTH）的异位产生。在大约50%的这些患者中，尽管进行了非常详细和广泛的检查，包括成像研究，如计算机断层扫描、磁共振成像和使用常规低剂量111-铟喷替曲肽（[111 In-DTPA-D-Phe]-喷替曲肽）的奥曲肽扫描，但仍无法找到ACTH的来源。该方案测试[18 F]-氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）扫描或使用更高剂量的[111 In-DTPA-D-Phe]-喷替曲肽是否可用于成功定位异位ACTH产生的来源。到目前为止，氟脱氧葡萄糖PET扫描在不到30%的患者中成功地识别了肿瘤。低剂量奥曲肽扫描在超过40%的患者中成功地定位了肿瘤。高剂量Octreoscan成功定位了约10%的患者的肿瘤。本研究继续探讨氟脱氧葡萄糖PET扫描和高剂量Octreoscan与常规成像方式相比是否可以为异位库欣患者提供额外的成像策略？s综合征。

Between 10% and 20% of patients with hypercortisolism (Cushing?s syndrome) have ectopic production of adrenocorticotropin hormone (ACTH). In approximately 50% of these patients, the source of ACTH cannot be found despite very detailed and extensive examination including imaging studies such as computed tomography scanning, magnetic resonance imaging, and octreotide scan using the conventional low dose of 111-indium pentetreotide ([111In-DTPA-D-Phe]-pentetreotide). This protocol tests whether [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning or use of a higher dose of [111In-DTPA-D-Phe]-pentetreotide can be used to localize successfully the source of ectopic ACTH production. To date fluorodeoxyglucose PET scanning successfully identified the tumor in less than 30% of patients.Low dose Octreoscan successfully localized the tumor in more than 40% of patients. High dose Octreoscan successfully localized the tumor in about 10% of patients. This study continues to find out whether fluorodeoxyglucose PET scanning and high dose Octreoscan compared to conventional imaging modalities can provide additional imaging strategies for patients with ectopic Cushing?s syndrome.